StockNews.com Upgrades Lantheus (NASDAQ:LNTH) to Buy

Lantheus (NASDAQ:LNTH - Get Free Report) was upgraded by equities researchers at StockNews.com from a "hold" rating to a "buy" rating in a research report issued to clients and investors on Friday.

Other equities analysts have also issued research reports about the company. B. Riley increased their target price on Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a research note on Thursday, July 25th. Leerink Partners increased their target price on Lantheus from $106.00 to $127.00 and gave the stock an "outperform" rating in a research note on Thursday, July 11th. Truist Financial reissued a "buy" rating and set a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research report on Friday. JMP Securities reduced their price target on Lantheus from $125.00 to $112.00 and set a "market outperform" rating on the stock in a research report on Thursday. Finally, Redburn Atlantic began coverage on Lantheus in a research report on Tuesday, September 3rd. They set a "buy" rating and a $175.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $122.50.

Lantheus Stock Performance

NASDAQ:LNTH traded down $0.81 on Friday, hitting $87.50. The company's stock had a trading volume of 1,618,137 shares, compared to its average volume of 993,186. The company has a current ratio of 4.68, a quick ratio of 4.41 and a debt-to-equity ratio of 0.55. The stock has a fifty day moving average of $107.33 and a two-hundred day moving average of $95.69. The firm has a market capitalization of $6.08 billion, a P/E ratio of 14.34 and a beta of 0.51. Lantheus has a one year low of $50.20 and a one year high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its earnings results on Wednesday, November 6th. The medical equipment provider reported $1.48 earnings per share for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. The company had revenue of $378.73 million for the quarter, compared to analyst estimates of $373.58 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. Research analysts predict that Lantheus will post 5.99 earnings per share for the current year.

Insider Buying and Selling at Lantheus

In other news, Director Gerard Ber sold 15,500 shares of the stock in a transaction on Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the transaction, the director now directly owns 21,221 shares in the company, valued at approximately $2,047,402.08. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 2.10% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. GAMMA Investing LLC raised its position in Lantheus by 184.1% during the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider's stock worth $26,000 after purchasing an additional 208 shares during the last quarter. Signaturefd LLC raised its position in Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock worth $35,000 after purchasing an additional 92 shares during the last quarter. Nkcfo LLC bought a new position in Lantheus during the 2nd quarter worth $47,000. UMB Bank n.a. raised its position in shares of Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock worth $47,000 after acquiring an additional 126 shares in the last quarter. Finally, Kathleen S. Wright Associates Inc. bought a new position in shares of Lantheus in the 3rd quarter worth about $51,000. 99.06% of the stock is owned by institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.